Pay in 4 interest-free payments of $6.05 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
ChEMBL v34 compound record for TIRZEPATIDE (CHEMBL4297839): max_phase 4 (approved), first_approval 2022, parenteral, GIP receptor agonist, first-in-class, black-box warning flag
This peptide is a true multitasker
Mistake #2: Stopping too early Feeling better after 2 weeks and stopping
[2,9] This connection between gut-derived peptides and neurological function is an active area of investigation
Researchers working with subjects outside this profile should account for several population-specific considerations that affect how the retatrutide escalation schedule performs and how outcomes should be interpreted
US$ 26.21
US$ 23.54
US$ 20.85
US$ 25.15
US$ 29.30
US$ 22.96
